This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
M

ASCO® 2024 Summary: "Comparative Review of Toxicities and Their Management With Bispecific Agents in MM and B-Cell NHL"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Monique Minnema
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Monique Minnema
0 views
June 7, 2024

Chapters

Introduction & Recommended Consensus Guidelines

00:00

FDA-Approved Bispecific Agents & Targets

01:11

Managing Cytokine Release Syndrome (CRS)

01:38

Tumor Flare & Injection Site Reactions

04:53

Cytopenias, Infections & Vaccination Strategies

06:40

Neurotoxicity & GPRC5D-Specific Toxicities

11:13

Patient Case Study & Take-Home Messages

14:56

Comments 0
Login to view comments. Click here to Login

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Featured Video

01:29
Incyte

Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD

2024 ASCO® Annual Meeting Insights Hub: Hematologic Oncology Videos

06:26
ecancer

Post-Transplant Cyclophosphamide Based GVHD Prophylaxis in Patients …

Feat. M. Al Malki, S. Devine
09:04
ecancer

ASCO® 2024 Insights: "Importance of MRD in Newly Diagnosed Mult…

Feat. X. Leleu
27:49
Insights from 2024 EHA Annual Meeting

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Feat. T. Badar
View All

Recommended

AUTOPLAY
16:57
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Lymphoma Highlights"

Feat. B. D. Cheson
17:52
Indy Hematology Review

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Feat. K. Anderson
16:42
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…

Feat. H. Hashmi
13:07
Moffitt Cancer Center

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Feat. J. Chavez
19:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…

Feat. R. Banerjee
27:47
Indy Hematology Review

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Feat. S. Smith
24:23
MyCancerHaven

Will CAR-Ts and Bispecifics Will Replace HSCT in Myeloma?

Feat. R. Vij, S. Al Hadidi
24:35
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 …

Feat. H. Hashmi
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
13:47
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maint…

Feat. B. Derman
06:33
Christopher Flowers

FDA Approval of Zanubrutinib in R/R FL: What You Need to Know

05:35
Saurabh Chhabra

Bispecifics & CAR-Ts in MM: How to Choose and How to Sequence

35:27
Louisville Hematology Highlights

Updates on Management of DLBCL

Feat. J. Leonard
20:19
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …

Feat. A. Paulus
10:04
Tara Graff

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

09:18
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Random…

Feat. J. Westin
36:10
Insights from 2024 EHA Annual Meeting

Highlights in Plasma Cell Disorders From ASCO® and EHA

Feat. S. Al Hadidi
12:38
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…

Feat. S. Usmani